AVXL:NSD-Anavex Life Sciences Corp (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.87

Change

-0.03 (-0.77)%

Market Cap

USD 0.23B

Volume

0.45M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase II clinical trials to treat Parkinson's disease; and preclinical clinical trials to treat Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Its preclinical drug candidates include ANAVEX 3-71, a central nervous system (CNS)-penetrable mono-therapy to treat Alzheimer's and Parkinson's diseases; ANAVEX 1-41, a sigma-1 agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.69 (-0.26%)

USD68.72B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

-7.73 (-1.37%)

USD60.13B 21.90 16.92
SGEN Seattle Genetics, Inc

+0.16 (+0.09%)

USD31.19B N/A N/A
MRNA Moderna, Inc

-1.99 (-2.96%)

USD26.58B N/A N/A
RPRX Royalty Pharma plc

-1.55 (-3.71%)

USD25.36B 35.72 9.73
ALXN Alexion Pharmaceuticals, Inc

-0.41 (-0.36%)

USD24.64B 30.43 27.52
BGNE BeiGene, Ltd

+1.89 (+0.69%)

USD24.64B N/A N/A
GMAB Genmab A/S

-1.06 (-2.94%)

USD23.46B 28.02 3.06
IMMU Immunomedics, Inc

+0.13 (+0.15%)

USD19.69B N/A N/A
INCY Incyte Corporation

-0.90 (-1.05%)

USD18.80B 47.64 35.20

ETFs Containing AVXL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 49.42% 79% C+ 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.42% 79% C+ 86% B
Trailing 12 Months  
Capital Gain 8.71% 50% F 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.71% 49% F 65% D
Trailing 5 Years  
Capital Gain -25.00% 54% F 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.00% 53% F 31% F
Average Annual (5 Year Horizon)  
Capital Gain -0.43% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.43% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 39.86% N/A N/A N/A N/A
Risk Adjusted Return -1.08% N/A N/A N/A N/A
Market Capitalization 0.23B 46% F 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 10.22 17% F 12% F
Price / Cash Flow Ratio -12.67 73% C 84% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -122.52% 23% F 10% F
Return on Invested Capital -141.68% 15% F 6% F
Return on Assets -61.12% 10% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 10.31 22% F 12% F
Short Percent 12.44% 23% F 16% F
Beta 1.62 44% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.